Pipeline

Through in-house discovery and strategic in-licensing with global best-in-class partners, we are accelerating the development and delivery of breakthrough medicines to patients around the world.

Brii Bio is building a pipeline of more than 10 novel therapeutic candidates that allows the Company to develop differentiated treatment options for patients based on two key methods:

The application of novel chemistry and extended-release formulation
The application of novel chemistry and extended-release formulation
Combination therapies to tackle the heterogeneity of complex diseases with a multi-prong approach
Combination therapies to tackle the heterogeneity of complex diseases with a multi-prong approach
Infectious Disease Programs
Indication
Program
Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights
Partners
Hepatitis B
More+
Preclinical:
Hepatitis B
Program:

BRII-179 (VBI-2601)/BRII-835 (VIR-2218) Combination

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Preclinical:
Hepatitis B
Program:

BRII-179 (VBI-2601)/PEG-IFN-α Combination 

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Preclinical:
Hepatitis B
Program:

BRII-877 (VIR-3434)(1)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
COVID-19
More+
Preclinical:
COVID-19
Program:

Amubarvimab/Romlusevimab Combination

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
China BLA approved and commercially launched
Under US EUA review
Brii Rights:
Global
Partners:
HIV
More+
Preclinical:
HIV
Program:

 BRII-732

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered
MDR/XDR Gram-negative Bacterial Infections
More+
Preclinical:
MDR/XDR Gram-negative Bacterial Infections
Program:

BRII-672 (ORAvance)(2)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Preclinical:
MDR/XDR Gram-negative Bacterial Infections
Program:

 BRII-693 (QPX9003)(2)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Preclinical:
MDR/XDR Gram-negative Bacterial Infections
Program:

BRII-636 (OMNIvance)(2)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
NTM Lung Disease
More+
Preclinical:
NTM Lung Disease
Program:

BRII-658 (Epetraborole)(3)

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Greater China*
Partners:
Central Nervous System Disease Programs
Indication
Program
Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights
Partners
PPD Treatment
More+
Preclinical:
PPD Treatment
Program:

BRII-296 

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered
PPD Prevention
More+
Preclinical:
PPD Prevention
Program:

BRII-296

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered
Anxiety & Depressive Disorder
More+
Preclinical:
Anxiety & Depressive Disorder
Program:

BRII-297

Preclinical
IND
Phase 1
Phase 2
Phase 3
NDA/BLA
Brii Rights:
Global
Partners:
Internally discovered

*Greater China – Mainland China, Macau, Hong Kong and Taiwan

Source: Company information

(1) The Phase 2 clinical trials have been conducted by VIR

(2) To this date, the development and clinical trials have been conducted by Qpex

(3) To this date, the development and clinical trials have been conducted by AN2

Partners